Teva said to be close to buying generic drug unit of Allergan
Petah Tikva, Israel
TEVA Pharmaceuticals is in advanced talks to buy the generic drug division of Allergan for about US$45 billion, a person briefed on the matter said on Saturday.
A deal could be announced as soon as Monday, this person said, though talks are ongoing and may still fall apart. Should an agreement be reached, it would be the latest huge deal in a wave of mergers within the healthcare space, a spree that has ranged from drugmakers to insurance providers.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue